AstraZeneca announced Tuesday, June 15, the failure of a phase III clinical trial for the prevention of symptomatic forms of Covid-19 in people exposed to the virus.
The trial did not achieve its main purpose
As many countries turned away from its first RNA vaccine, AstraZeneca was in the process of testing a new treatment on the prevention of symptomatic forms of the coronavirus. The laboratory Franco-Swedish announced Tuesday, June 15, 2015 that this treatment has not proven its effectiveness on people exposed to the virus.
” Trial failed to achieve primary goal of preventing symptomatic Covid-19 cases after exposure “ virus, AstraZeneca explained in a statement.
33% reduction in symptoms
Antibody treatment was in phase III of development, which means that the research was well advanced. The laboratory had set up large-scale clinical trials to measure the safety and effectiveness of the brand new treatment. Astrazeneca compared its antibody treatment to code name AZD7442 to placebo. The treatment only reduced the risk of developing Covid-19 with symptoms by 33%.
The study was carried out on 1,121 unvaccinated people. Of these, 23 developed a symptomatic form of the disease in the AZD7442 group (which had 749 patients) and 17 in the placebo group (372).